Axsome TherapeuticsAXSM
AXSM
About: Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Employees: 569
0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 23
8% more funds holding
Funds holding: 254 [Q2] → 274 (+20) [Q3]
4% more capital invested
Capital invested by funds: $3.32B [Q2] → $3.45B (+$136M) [Q3]
2% more call options, than puts
Call options by funds: $95.7M | Put options by funds: $94M
5.89% less ownership
Funds ownership: 86.83% [Q2] → 80.94% (-5.89%) [Q3]
13% less repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 93
27% less funds holding in top 10
Funds holding in top 10: 11 [Q2] → 8 (-3) [Q3]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$116
3%
upside
Avg. target
$147
30%
upside
High target
$190
68%
upside
7 analyst ratings
7 positive
100%
0 neutral
0%
0 negative
0%
Mizuho Graig Suvannavejh 52% 1-year accuracy 16 / 31 met price target | 21%upside $137 | Outperform Maintained | 3 Feb 2025 |
Truist Securities Joon Lee 53% 1-year accuracy 23 / 43 met price target | 68%upside $190 | Buy Maintained | 3 Feb 2025 |
RBC Capital Brian Abrahams 17% 1-year accuracy 13 / 77 met price target | 27%upside $143 | Outperform Maintained | 3 Feb 2025 |
HC Wainwright & Co. Raghuram Selvaraju 42% 1-year accuracy 138 / 329 met price target | 68%upside $190 | Buy Maintained | 31 Jan 2025 |
Needham Ami Fadia 51% 1-year accuracy 84 / 165 met price target | 18%upside $133 | Buy Reiterated | 13 Jan 2025 |
Financial journalist opinion
Based on 6 articles about AXSM published over the past 30 days
Positive
Zacks Investment Research
4 days ago
Axsome Gets FDA Nod for New Migraine Drug Symbravo, Stock Rises
The FDA approves AXSM's Symbravo for the acute treatment of migraine with or without aura in adults. The latest nod diversifies its commercial portfolio.
Neutral
GlobeNewsWire
4 days ago
Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader
NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, will host a virtual investor event and conference call today at 8:00 AM Eastern Time to discuss the U.S. Food and Drug Administration (FDA) approval of SYMBRAVO®, a novel multi-mechanistic approach to treating migraine that targets multiple pathways underlying a migraine attack.
Positive
Reuters
5 days ago
US FDA approves Axsome Therapeutics' migraine drug
The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday.
Neutral
GlobeNewsWire
5 days ago
Axsome Therapeutics Announces FDA Approval of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults
A single oral dose of SYMBRAVO provided rapid migraine pain freedom and return to normal functioning within 2 hours, and sustained efficacy through 24 and 48 hours
Positive
Zacks Investment Research
1 week ago
Axsome Shares Rise 19% in a Month: What's Driving the Rally?
AXSM stock is riding on upbeat preliminary 2024 results. The company's depression drug, Auvelity, drives its top line while Sunosi diversifies its business.
Positive
Zacks Investment Research
3 weeks ago
Axsome (AXSM) Moves 11.5% Higher: Will This Strength Last?
Axsome (AXSM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Positive
Seeking Alpha
1 month ago
Axsome Therapeutics Remains A Buy Despite AXS-05's Mixed Results
Axsome Therapeutics shows strong revenue growth from Auvelity and Sunosi, with promising late-stage pipeline drugs for migraine, fibromyalgia, and narcolepsy. Late-stage pipeline milestones include AXS-07 for migraine (PDUFA: January 31, 2025), AXS-12 for narcolepsy, and AXS-14 for fibromyalgia. Despite mixed Phase 3 results for AXS-05 in Alzheimer's agitation, the overall data is favorable, supporting a bullish outlook.
Positive
Benzinga
1 month ago
Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results
On Monday, Axsome Therapeutics, Inc. AXSM released data from ACCORD-2, ADVANCE-2, and long-term safety trials AXS-05 (dextromethorphan-bupropion) in Alzheimer's disease agitation.
Negative
Investors Business Daily
1 month ago
Axsome Flashes A Bearish Signal On Mixed Results In Alzheimer's Agitation
Shares of Axsome Therapeutics dropped Monday on mixed test results for its Alzheimer's disease agitation treatment. The post Axsome Flashes A Bearish Signal On Mixed Results In Alzheimer's Agitation appeared first on Investor's Business Daily.
Negative
Benzinga
1 month ago
Axsome Therapeutics, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling more than 50 points on Monday.
Charts implemented using Lightweight Charts™